Colchicine for Secondary Prevention After Ischemic Stroke (CHANCE-3 EX)
- Conditions
- Stroke
- Interventions
- Registration Number
- NCT07035405
- Lead Sponsor
- Beijing Tiantan Hospital
- Brief Summary
The role of colchicine in the secondary prevention of ischemic stroke has not been determinded. This multicenter, randomized, double-blind, placebo-controlled, event-driven clinical trial of CHANCE-3 EX was aimed to assess the efficacy and safety of low-dose colchicine versus placebo on reducing the risk of recurrent ischemic stroke, myocardial infarction and vascular death in patients with minor-to-moderate ischemic stroke.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- NOT_YET_RECRUITING
- Sex
- All
- Target Recruitment
- 7500
- An age of 18-80 years old
- Minor-to-moderate ischemic stroke (NIHSS<15 at randomization; confirmed by CT or MRI)
- Within 7-30 days after the most recent qualifying stroke onset
- Informed consent signed
- Iatrogenic causes (angioplasty or surgery) of stroke
- mRS>3 at randomization
- Known allergy, sensitivity or intolerance to colchicine
- Inflammatory bowel disease (Crohn's or ulcerative colitis) or chronic diarrhea
- Symptomatic peripheral neuropathy or pre-existing progressive neuromuscular disease or with creatine kinase (CK) level > 3 times the upper limit of normal as measured within the past 30 days and determined to be non-transient through repeat testing
- A history of cirrhosis, chronic active hepatitis or severe hepatic disease
- Impaired hepatic (ALT or AST > three times the upper limit of normal range) or kidney (creatinine exceeding 1.5 times of the upper limit of normal range or eGFR less than 50 ml/min) function at randomization
- Anemia (haemoglobin <10g/dL), thrombocytopenia (platelet count <100×109/L) or leucopenia (white blood cell count <3×109/L) at randomization
- Comorbid gout or other indications for colchicine use
- Active infection at randomization (including respiratory tract infection, urinary tract infection, or gastroenteritis)
- Requiring chronic immunosuppressant, glucocorticoid, or nonsteroidal anti-inflammatory drugs therapy (except aspirin) during the study
- Usage of contraindicated medications for colchicine at randomization: moderate or strong CYP3A4 inhibitors (clarithromycin, erythromycin, telithromycin, other macrolide antibiotics, ketoconazole, itraconazole, voriconazole, ritonavir, atazanavir, indinavir, other HIV protease inhibitors, verapamil, diltiazem, quinidine, digoxin, disulfiram, etc) or P-gp inhibitors (cyclosporine)
- Participating in another clinical trial with an investigational drug or device concurrently or during the last 30 days
- Women of childbearing age who were not practicing reliable contraception and did not have a documented negative pregnancy test
- Severe non-cardiovascular comorbidity, active malignant tumors or terminal-stage illnesses, with a life expectancy of less than 2 years
- Clinically significant drug or alcohol abuse in the past year
- Any other conditions deemed unsuitable for participation in this study or inability to complete study procedures, including but not limited to mental disorders, cognitive or emotional impairments, or physical conditions that may compromise compliance with study protocols and follow-up visits
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Colchicine Group Colchicine 0.5 mg Patients in this arm will receive low-dose colchicine in addition to standard medical care Placebo Colchicine Group Placebo colchicine Patients in this arm will receive placebo colchicine in addition to standard medical care
- Primary Outcome Measures
Name Time Method First Event of ischemic stroke, myocardial infarction and vascular death From randomization to occurrence of the first event, with a median follow-up time of 24 months The descriptive statistics are the number of participants having at least one of the composites of the primary endpoint.
- Secondary Outcome Measures
Name Time Method Ischemic stroke From randomization to event, with a median follow-up time of 24 months. The descriptive statistics are presented as the number of participants having had ischemic stroke.
Myocardial Infarction From randomization to event, with a median follow-up time of 24 months. The descriptive statistics are presented as the number of participants having had myocardial infarction.
Vascular death From randomization to death, with a median follow-up time of 24 months. The descriptive statistics are presented as the number of participants having had a vascular death.
mRS 0-1 at 1 year or ≥1-point improvement in mRS score from baseline to 1 year At 1 year The descriptive statistics are presented as the number of participants having had mRS 0-1 at 1 year or ≥1-point improvement in mRS score from baseline to 1 year.
mRS shift At 1 year
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.